| Sep 6 |
Aclarion Added to PRISM Emerging Medical Devices Index
|
| Sep 5 |
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
|
| Aug 29 |
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
|
| Aug 21 |
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
|
| Aug 17 |
Aclarion Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 15 |
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
|
| Aug 14 |
Aclarion Announces First Commercial Agreement in Michigan
|
| Aug 13 |
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
|
| Jul 9 |
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
|
| Jun 26 |
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
|
